Previous 10 | Next 10 |
home / stock / lzagf / lzagf news
iSpecimen has filed to raise $20 million in an IPO. The firm operates a human biospecimen online marketplace. ISPN has grown from a small revenue base and operates in a promising industry, so I look forward to learning about the IPO's pricing and valuation assumptions. For f...
The contingent value right issued to Celgene shareholders after the Bristol-Myers acquisitions are dependent on approval of Liso-cell and Ide-cell. For Liso-cell to be approved the FDA seems insistent on inspection of a Texas-based Lonza facility. Twitter sources point toward a ph...
Under its new supply agreement with the United Kingdom's government, Moderna (MRNA) will supply a total of 7M mRNA-1273 doses to the U.K., beginning in March.The company said it's continuing to scale up its global manufacturing to be able to deliver ~500M doses per year and possibly...
Original post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...
More vaccine news to catch up on - previous updates and specific topic posts on this subject were on June 15 , on June 11 , on May 26, on May 18 (with two other posts), on May 14, on May 1, on April 23, and on April 15 (author's note: yikes). Keep in mind that some of those posts were update...
Investment Thesis The stakes have never been higher for Moderna, Inc. ( MRNA ) as it battles a myriad of competitors in the race for a successful COVID-19 vaccine. The long and arduous process of vaccine development and testing has slim monetary gains and a low chance of success. Despite a...
Lonza Group Ltd (LZAGF) Q1 2020 Earnings Conference Call April 17, 2020 7:00 AM ET Company Participants Albert Baehny - Chairman & Interim Chief Executive Officer Conference Call Participants KC Arikatla - Goldman Sachs Patrick Rafaisz - UBS Peter Welford - Jefferies ...
Lonza Group ( OTCPK:LZAGF ) maintains a positive performance in Q1 2020, with Q1 net sales of CHF1.6B (+7.4% Q/Q constant exchange rate). More news on: Lonza Group Ltd, Lonza Group Ltd, Earnings news and commentary, Read more ...
Thesis summary I believe that Lonza (LZAGF) is a great business that is underappreciated by the market due to its high business complexity, but strong growth should continue on the back of synergies, several global megatrends, and focus on the company's healthcare continuum. Also, the comp...
The following slide deck was published by Lonza Group Ltd in conjunction with their 2019 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Lonza Group AG Company Name:
LZAGF Stock Symbol:
OTCMKTS Market:
NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today ...